Chimeric antigen receptor T-cell therapy: Difference between revisions
From IDWiki
(Created page with "== Background == * T cells are retrieved from a patient, genetically modified to add a chimeric antigen receptor (CAR) that is specific to the targetted cancer antigen, and r...") |
No edit summary |
||
Line 27: | Line 27: | ||
|Idecabtagene vicleucel |
|Idecabtagene vicleucel |
||
|multiple myeloma |
|multiple myeloma |
||
+ | |B-cell maturation antigen |
||
− | |BCMA |
||
|11.8 month media PFS |
|11.8 month media PFS |
||
|- |
|- |
||
Line 35: | Line 35: | ||
|18.8 month median OS |
|18.8 month median OS |
||
|} |
|} |
||
+ | |||
+ | == Safety == |
||
+ | |||
+ | === Adverse Effects === |
||
+ | |||
+ | * Prolonged cytopenias and B-cell hypoplasia (causing [[hypogammaglobulinemia]]) |
||
+ | * Loss of immunity to previous vaccinations |
||
+ | ** Start revaccinating about 6 months after infusion |
||
+ | |||
+ | === Cytokine Release Syndrome === |
||
+ | |||
+ | * Caused by harmful immune system activation |
||
+ | * Fever is a defining feature, with hypotension and hypoxia in severe disease |
||
+ | ** Often mimics sepsis |
||
+ | * May also results in [[DIC]], multiorgan failure, and death |
||
+ | * Treated with corticosteroids and [[tocilizumab]], an IL-6 inhibitor |
||
+ | * Usually self-limited |
||
+ | |||
+ | === Immune Effector Cell-Associated Neurotoxicity Syndrome === |
||
+ | |||
+ | * ICANS |
||
+ | * Word-finding difficulty, aphasia, or confusion |
||
+ | * In severe disease, altered level of consciousness, motor impairment, and cerebral edema |
||
+ | * Treated with corticosteroids |
||
+ | * Most cases resolve |
||
+ | |||
[[Category:Hematology]] |
[[Category:Hematology]] |
||
[[Category:Oncology]] |
[[Category:Oncology]] |
Revision as of 07:18, 1 February 2022
Background
- T cells are retrieved from a patient, genetically modified to add a chimeric antigen receptor (CAR) that is specific to the targetted cancer antigen, and reinfused into the patient following a short course of chemotherapy
- Used for relapsed or refractory B-cell acute lymphoblastic leukemia and high-grade B-cell lymphoma
Product | Indications | Target Antigen | Survival |
---|---|---|---|
Tisagenlecleucel | B-ALL and high-grade B-cell lymphoma | CD19 | 76% 1-year OS in B-ALL; 8.3 month median OS in B-cell lymphoma |
Axicabtagene ciloleucel | high-grade B-cell lymphoma | CD19 | 58% 18-month OS |
Brexucabtagene autoleucel | mantle cell lymphoma | CD19 | 83% 1-year OS |
Idecabtagene vicleucel | multiple myeloma | B-cell maturation antigen | 11.8 month media PFS |
Lisocabtagene maraleucal | high-grade B-cell lymphoma | CD19 | 18.8 month median OS |
Safety
Adverse Effects
- Prolonged cytopenias and B-cell hypoplasia (causing hypogammaglobulinemia)
- Loss of immunity to previous vaccinations
- Start revaccinating about 6 months after infusion
Cytokine Release Syndrome
- Caused by harmful immune system activation
- Fever is a defining feature, with hypotension and hypoxia in severe disease
- Often mimics sepsis
- May also results in DIC, multiorgan failure, and death
- Treated with corticosteroids and tocilizumab, an IL-6 inhibitor
- Usually self-limited
Immune Effector Cell-Associated Neurotoxicity Syndrome
- ICANS
- Word-finding difficulty, aphasia, or confusion
- In severe disease, altered level of consciousness, motor impairment, and cerebral edema
- Treated with corticosteroids
- Most cases resolve